Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369712 | 0.80 | HRH3 (0.54) | CD44AKR1C3HRH3CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL4512719 | 0.78 | HRH3 (0.53) | CD44AKR1C3HRH3CARM1PRMT6 | |
| SCHEMBL30443592 | 0.77 | KDM4E (0.49) | CARM1 | |
| SCHEMBL3450752 | 0.77 | KDM4E (0.49) | CARM1 | |
| SCHEMBL7797939 | 0.77 | HRH3 (0.46) | CD44HRH3 | |
| SCHEMBL4780438 | 0.76 | HRH3 (0.53) | CD44AKR1C3HRH3 | |
| SCHEMBL16268875 | 0.76 | HRH3 (0.42) | HRH3 | |
| SCHEMBL14272178 | 0.76 | PNMT (0.50) | — | |
| Bromide SCHEMBL11735060 | 0.76 | HRH3 (0.45) | CD44HRH3 | |
| SCHEMBL31454357 | 0.74 | CD44 (0.40) | CD44AKR1C3HRH3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920010-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-20 | — | — | US | disclosed |
| EP-3004082-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004082-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191929-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | CD44 2366/4885AKR1C3 814/4885HRH3 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.